The authors show that EVER can correctly predict mutations that mediate resistance to BCR-ABL-targeting drugs in chronic myeloid leukemia and, through in vitro experiments, provide insights into the mechanism of resistance. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.